HilleVax to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus CVR

HilleVax (NASDAQ: HLVX) has entered into a definitive merger agreement to be acquired by XOMA Royalty (NASDAQ: XOMA) in a structured deal. Shareholders will receive $1.95 in cash per share plus a non-transferable contingent value right (CVR).

The CVR includes potential payments from: (1) excess cash above $102.95M, (2) 90-100% of Boston office lease savings, and (3) 90% of proceeds from any norovirus vaccine program sales within specific timeframes. The deal has received unanimous board approval, with 22.9% of stockholders already committed through support agreements.

The tender offer will commence by August 18, 2025, with the acquisition expected to close in September 2025, subject to standard conditions including majority shareholder approval and minimum cash balance requirements.

https://www.stocktitan.net/news/HLVX/hille-vax-enters-into-a-definitive-agreement-to-be-acquired-by-xoma-jswovusoku9x.html